Overview

Gender

male

Investor Type

Investment Partner

Thomas O. Daniel, M.D. has served as a director since May 2012. Dr. Daniel has served as President, Research and Early Development of Celgene since December 2006.

Prior to joining Celgene, he served as the Chief Scientific Officer and a member of the board of directors at Ambrx Inc., a biotechnology company focused on discovering and developing protein-based therapeutics. Dr. Daniel previously served as Vice President, Research at Amgen Inc., where he was Research Site Head of Amgen Washington and Therapeutic Area Head of Inflammation.

Dr. Daniel received an M.D. from the University of Texas, Southwestern, and completed medical residency at Massachusetts General Hospital.